Insider Selling: Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $124,091.98 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $124,091.98. Following the sale, the insider owned 1,317,389 shares of the company’s stock, valued at approximately $6,073,163.29. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total transaction of $423,377.00.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.71, for a total transaction of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total transaction of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.51, for a total transaction of $1,172,811.97.

Taysha Gene Therapies Stock Up 2.0%

TSHA opened at $4.57 on Friday. The business’s fifty day simple moving average is $5.11 and its 200 day simple moving average is $4.09. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.25 billion, a PE ratio of -13.85 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. As a group, research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in TSHA. Pictet Asset Management Holding SA bought a new stake in Taysha Gene Therapies in the 4th quarter worth $106,000. Vanguard Group Inc. boosted its holdings in shares of Taysha Gene Therapies by 3.3% during the fourth quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock worth $72,973,000 after purchasing an additional 418,192 shares during the period. NBC Securities Inc. bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth about $291,000. Arizona State Retirement System bought a new stake in shares of Taysha Gene Therapies in the fourth quarter worth about $207,000. Finally, Chicago Partners Investment Group LLC increased its holdings in Taysha Gene Therapies by 1.5% during the 4th quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after purchasing an additional 2,504 shares during the period. Hedge funds and other institutional investors own 77.70% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on TSHA shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of Taysha Gene Therapies in a research report on Friday, November 14th. Citizens Jmp upped their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 5th. UBS Group set a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Finally, Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.67.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.